Principles of Local Drug Delivery to the Inner Ear
Overview
Psychiatry
Authors
Affiliations
As more and more substances have been shown in preclinical studies to be capable of preventing damage to the inner ear from exposure to noise, ototoxic drugs, ischemia, infection, inflammation, mechanical trauma and other insults, it is becoming very important to develop feasible and safe methods for the targeted delivery of drugs to specific regions in the inner ear. Recently developed methods for sampling perilymph from the cochlea have overcome major technical problems that have distorted previous pharmacokinetic studies of the ear. These measurements show that drug distribution in perilymph is dominated by passive diffusion, resulting in large gradients along the cochlea when drugs are applied intratympanically. Therefore, in order to direct drugs to specific regions of the ear, a variety of delivery strategies are required. To target drugs to the basal cochlear turn and vestibular system while minimizing exposure of the apical cochlear turns, single one-shot intratympanic applications are effective. To increase the amount of drug reaching the apical cochlear turns, repeated intratympanic injections or controlled-release drug delivery systems, such as biodegradable biopolymers or catheters and pumps, are more effective. However, if the applied substance does not easily pass through the round window membrane, or if a more widespread distribution of drug in the ear is required, then intralabyrinthine injections of the substance may be required. Intralabyrinthine injection procedures, which are currently in development in animals, have not yet been proven safe enough for human use.
Voruz F, Feng S, Breil E, Yu M, Hammer D, Aksit A Drug Deliv Transl Res. 2025; .
PMID: 40009130 DOI: 10.1007/s13346-025-01821-z.
Hearing loss during chemotherapy: prevalence, mechanisms, and protection.
Kessler L, Koo C, Richter C, Tan X Am J Cancer Res. 2024; 14(9):4597-4632.
PMID: 39417180 PMC: 11477841. DOI: 10.62347/OKGQ4382.
Boreel M, van Esch B, Schermer T, Mol B, van Benthem P, Bruintjes T BMJ Open. 2024; 14(8):e076872.
PMID: 39209781 PMC: 11367374. DOI: 10.1136/bmjopen-2023-076872.
Yuan R, Wang B, Wang Y, Liu P Oncol Ther. 2024; 12(2):257-276.
PMID: 38760612 PMC: 11187037. DOI: 10.1007/s40487-024-00279-2.
Manrique-Huarte R, Alvarez De Linera-Alperi M, Perez-Fernandez N, Manrique M Front Neurol. 2024; 15:1363481.
PMID: 38469594 PMC: 10926955. DOI: 10.3389/fneur.2024.1363481.